<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Na TU</submitter><pubmed_abstract>A chemodiverse library of new semi-synthetic antimicrobial peptides is reported herein. The polymyxin B nonapeptide (PMBN) holds promise as a developmental platform to access potent antimicrobial lipopeptide derivatives that circumvent the serious side effects of natural polymyxins used in clinical settings. By combining our unique radical thiol-ene lipidation strategy (CLipPA) with a chemoenzymatic synthesis, we achieved the chemoselective re-functionalisation of semi-synthetic PMBN, affording a family of potent "soft drugs" decorated with linear, cyclo- and branched alkyl and aromatic esters of varying steric properties. The high efficiency of this late-stage diversification strategy is demonstrated for lipopeptide semi-synthesis. In this process, the significance of the lipid orientatio</pubmed_abstract><journal>RSC medicinal chemistry</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12907753</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Introducing CLipPA lipid chemodiversity to enzymatically truncated polymyxin B: a soft drug strategy to combat Gram-negative pathogens.</pubmed_title><pmcid>PMC12907753</pmcid><pubmed_authors>Siow A</pubmed_authors><pubmed_authors>Goggin BL</pubmed_authors><pubmed_authors>Allison JR</pubmed_authors><pubmed_authors>Sander V</pubmed_authors><pubmed_authors>Cook GM</pubmed_authors><pubmed_authors>Daysh Z</pubmed_authors><pubmed_authors>Ferguson SA</pubmed_authors><pubmed_authors>Brimble MA</pubmed_authors><pubmed_authors>Owen JG</pubmed_authors><pubmed_authors>Painter GF</pubmed_authors><pubmed_authors>Campbell G</pubmed_authors><pubmed_authors>Hanna CC</pubmed_authors><pubmed_authors>Na TU</pubmed_authors><pubmed_authors>Hermant YO</pubmed_authors><pubmed_authors>Harris PWR</pubmed_authors><pubmed_authors>Cameron AJ</pubmed_authors><pubmed_authors>Chan STS</pubmed_authors><pubmed_authors>Davidson AJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Introducing CLipPA lipid chemodiversity to enzymatically truncated polymyxin B: a soft drug strategy to combat Gram-negative pathogens.</name><description>A chemodiverse library of new semi-synthetic antimicrobial peptides is reported herein. The polymyxin B nonapeptide (PMBN) holds promise as a developmental platform to access potent antimicrobial lipopeptide derivatives that circumvent the serious side effects of natural polymyxins used in clinical settings. By combining our unique radical thiol-ene lipidation strategy (CLipPA) with a chemoenzymatic synthesis, we achieved the chemoselective re-functionalisation of semi-synthetic PMBN, affording a family of potent "soft drugs" decorated with linear, cyclo- and branched alkyl and aromatic esters of varying steric properties. The high efficiency of this late-stage diversification strategy is demonstrated for lipopeptide semi-synthesis. In this process, the significance of the lipid orientatio</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Feb</publication><modification>2026-07-16T05:05:21.48Z</modification><creation>2026-07-09T10:38:05.67Z</creation></dates><accession>S-EPMC12907753</accession><cross_references><pubmed>41705127</pubmed><doi>10.1039/d5md01141h</doi></cross_references></HashMap>